NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Purchases $16,071.93 in Stock

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) major shareholder Poplar Point Capital Partners purchased 25,511 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average cost of $0.63 per share, with a total value of $16,071.93. Following the purchase, the insider now owns 808,277 shares in the company, valued at $509,214.51. This represents a 3.26 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

• On Friday, January 31st, Poplar Point Capital Partners bought 70,685 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.65 per share, with a total value of $45,945.25.
• On Monday, January 27th, Poplar Point Capital Partners purchased 31,703 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.69 per share, for a total transaction of $21,875.07.
• On Thursday, February 20th, Poplar Point Capital Partners acquired 1,836 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.63 per share, with a total value of $1,156.68.
• On Tuesday, February 18th, Poplar Point Capital Partners acquired 3,222 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.66 per share, with a total value of $2,126.52.
• On Monday, February 3rd, Poplar Point Capital Partners bought 2,597 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average price of $0.64 per share, for a total transaction of $1,662.08.
• On Friday, March 7th, Poplar Point Capital Partners acquired 102 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.55 per share, for a total transaction of $56.10.
• On Tuesday, March 4th, Poplar Point Capital Partners bought 4,000 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.58 per share, with a total value of $2,320.00.
• On Thursday, February 27th, Poplar Point Capital Partners purchased 385 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average price of $0.61 per share, for a total transaction of $234.85.
• On Tuesday, February 25th, Poplar Point Capital Partners acquired 25,033 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.62 per share, with a total value of $15,520.46.
• On Wednesday, March 12th, Poplar Point Capital Partners bought 11,837 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.62 per share, for a total transaction of $7,338.94.

NovaBay Pharmaceuticals Stock Up 7.3 %

NYSE NBY traded up $0.04 during trading on Tuesday, hitting $0.60. The company’s stock had a trading volume of 176,212 shares, compared to its average volume of 188,552. NovaBay Pharmaceuticals, Inc. has a 52 week low of $0.36 and a 52 week high of $9.08. The firm has a market cap of $3.49 million, a P/E ratio of -0.01 and a beta of 0.90. The firm has a 50 day moving average price of $0.60 and a 200 day moving average price of $0.63.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals in a research report on Thursday, April 10th. They set a “hold” rating for the company.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.